Abstract

BackgroundThe most common cause of ocular morbidity in developed countries is dry eye, many cases of which are due to lacrimal insufficiency. Dry eye affects approximately 10 million in the United States., most of whom are women. In the U.S. alone, an estimated 2 million Sjögren's syndrome patients have dysfunctional lacrimal glands and severe dry eye, and there is no satisfactory treatment. These patients would benefit if their lacrimal tissue function could be restored.MethodsThe effect of adenovirus-mediated transfer of tumor necrosis factor (TNF)-α inhibitor gene on induced autoimmune dacryoadenitis was evaluated in a rabbit model. Soluble transgene protein was detected in tears by ELISA for 7 days following transduction.ResultsTwo weeks after induction of disease with activated lymphocytes, tear production, as determined by Schirmer testing, was reduced by about 40%, while tear film stability, as measured by tear breakup time (BUT), declined by 43%. Adenovirus-mediated gene therapy using AdTNFRp55-Ig given 2 weeks after disease induction, resulted in the return of tear production to normal levels by week 4. In the treated disease group, tear BUT improved significantly by week 4. Rose bengal scores, an indicator of corneal surface defects, increased after disease induction and declined after gene therapy. In the lacrimal gland, the CD4 to CD8 T cell ratio was 4:1 in the disease group compared to 1:2 in the treated group. Infiltration of T cells and CD18+ cells was reduced approximately 50% after gene therapy.ConclusionWe concluded that therapeutic levels of soluble TNF inhibitor were achieved in the lacrimal gland and on the corneal surface. Anti-inflammatory cytokine gene expression might offer a potential therapeutic modality for the treatment of autoimmune dacryoadenitis, once suitable vectors become available.

Highlights

  • The most common cause of ocular morbidity in developed countries is dry eye, many cases of which are due to lacrimal insufficiency

  • In a prophylactic study utilizing the same clinical parameters, we reported evidence that soluble TNFinhibitor protein partially suppresses the appearance of Sjögren's syndrome-like features of reduced basal tear production, as well as the immunohistopathology associated with induced autoimmune dacryoadenitis [12]

  • Induced autoimmune dacryoadenitis and clinical assessment Autologous peripheral blood lymphocytes (PBL), activated by co-culture with rabbit lacrimal gland epithelial cells, induced dacryoadenitis within 2 weeks when injected into the donor rabbit's remaining contralateral lacrimal gland

Read more

Summary

Introduction

The most common cause of ocular morbidity in developed countries is dry eye, many cases of which are due to lacrimal insufficiency. In the U.S alone, an estimated 2 million Sjögren's syndrome patients have dysfunctional lacrimal glands and severe dry eye, and there is no satisfactory treatment. The inflammatory infiltrates produce toxic factors that act as immune mediators, resulting in reduced secretory function caused by secretory tissue atrophy and dysfunction of the surviving tissue [4,5] Both murine and rabbit models have been used to elucidate the mechanisms of autoimmune lacrimal gland disease. Our Ocular Surface Center research group reported that autologous peripheral blood lymphocytes (PBL) proliferate when co-cultured with rabbit lacrimal gland epithelial cells [6] These activated lymphocytes induced dacryoadenitis within 2 weeks when injected into the donor rabbit's remaining contralateral gland, providing an in vivo model of autoimmune dacryoadenitis [7,8]. The induced lacrimal gland dysfunction, characterized by reduced basal tear production, reduced tear stability, abnormal corneal surface staining, and increased presence of CD4+ T cells, mimics several important features of keratoconjunctivitis sicca and Sjögren's syndrome

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call